A number of investment brokers have recently updated their price targets on shares of Abbott Laboratories (NYSE:ABT). According to the latest broker reports outstanding on Monday 9th of May, 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 analysts “neutral”, 0 analysts “sell” and 0 analysts “strong sell”.

Most recent broker ratings

04/29/2016 – Abbott Laboratories had its “overweight” rating reiterated by analysts at Wells Fargo.

04/29/2016 – Abbott Laboratories had its “hold” rating reiterated by analysts at S&P Capital IQ.

04/29/2016 – Abbott Laboratories had its “buy” rating reiterated by analysts at Gabelli.

04/28/2016 – Abbott Laboratories had its “buy” rating reiterated by analysts at BTIG Research. They now have a USD 45 price target on the stock.

04/11/2016 – Abbott Laboratories had its “outperform” rating reiterated by analysts at RBC Capital. They now have a USD 48 price target on the stock.

03/28/2016 – Abbott Laboratories had its “buy” rating reiterated by analysts at Stifel Nicolaus. They now have a USD 47 price target on the stock.

03/15/2016 – Abbott Laboratories had its “buy” rating reiterated by analysts at Jefferies. They now have a USD 47 price target on the stock.

02/05/2016 – Abbott Laboratories was upgraded to “buy” by analysts at Argus. They now have a USD 50 price target on the stock.

02/01/2016 – Abbott Laboratories had its “neutral” rating reiterated by analysts at UBS. They now have a USD 41 price target on the stock.

01/29/2016 – Abbott Laboratories had its “outperform” rating reiterated by analysts at Raymond James. They now have a USD 42 price target on the stock.

01/29/2016 – Abbott Laboratories had its “market perform” rating reiterated by analysts at Leerink Swann. They now have a USD 40 price target on the stock.

01/29/2016 – Abbott Laboratories had its “neutral” rating reiterated by analysts at Goldman Sachs. They now have a USD 40 price target on the stock.

01/29/2016 – Abbott Laboratories had its “outperform” rating reiterated by analysts at Cowen. They now have a USD 44 price target on the stock.

01/29/2016 – Abbott Laboratories had its “outperform” rating reiterated by analysts at BMO Capital Markets. They now have a USD 45 price target on the stock.

01/29/2016 – Abbott Laboratories was downgraded to “market perform” by analysts at William Blair.

The share price of Abbott Laboratories (NYSE:ABT) was down -1.38% during the last day of trading, with a day high of 38.40. 11399947 shares were traded during the last session.

The stock’s 50 day moving average is 41.80 and its 200 day moving average is 42.02. The stock’s market capitalization is 55.94B. Abbott Laboratories has a 52-week low of 36.00 and a 52-week high of 51.74.

View other investors thoughts on Abbott Laboratories with our new Stock Talk discussion platform. Sign up for free to contribute to the community and view research provided from other investors for any stock listed on the LSE, NYSE or NASDAQ.